USA –Amgen has announced the issuance of its first US$750 million green bond, with a semi-annual coupon of 3% and a maturity date of 2029, to advance the environmental goals…
Read MoreTag: Amgen
Novartis and Amgen settle lawsuit over migraine drug Aimovig
SWITZERLAND – Novartis and Amgen, who have been feuding for years over a failed deal, have agreed to lay down their grievances and move on. The two companies have been…
Read MoreAmgen collaborates with Arrakis to develop targeted RNA degraders
USA – Amgen and Arrakis Therapeutics have announced a collaboration to develop RNA degrader therapeutics for a variety of difficult-to-drug targets. The collaboration will focus on developing a new class…
Read MoreAmgen strikes US$1.9 billion deal to develop multispecific protein therapeutics
USA – Amgen and Generate Biomedicines have formed a collaboration to discover and develop protein therapeutics for five clinical targets. Amgen will pay US$50 million in upfront funding for five…
Read MoreViatris and Biocon consider merger of their biosimilars into a US$10B standalone company
INDIA – Viatris and India’s Biocon Biologics are debating whether to further integrate their already deeply entwined biosimilar businesses into a US$10 billion standalone company, according to Moneycontrol, an Indian…
Read MoreLilly bags a license worth US$1.5 billion for a batch of metabolic candidates with Regor Therapeutics
USA – Eli Lilly has formed a multi-year collaboration with China-based Regor Therapeutics Group to discover and develop new therapies for metabolic disorders in a deal that will see the…
Read MoreBayer, Dr. Reddy’s settle patent row over cancer drug Nexavar
GERMANY – Bayer Healthcare and Amgen subsidiary Onyx Pharmaceuticals have agreed to drop their patent lawsuit against Dr. Reddy’s Laboratories over the proposed generic version of Nexavar. According to a…
Read More